NOTES_NNS TO_TO THE_DT CONSOLIDATED_JJ FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD As_IN required_VBN by_IN IFRS_NNP 3_CD ,_, the_DT fair_JJ value_NN adjustment_NN to_TO inventory_NN for_IN finished_VBN goods_NNS represents_VBZ the_DT selling_NN price_NN of_IN the_DT goods_NNS less_JJR costs_NNS to_TO dispose_VB and_CC a_DT reasonable_JJ profit_NN allowance_NN for_IN the_DT selling_NN effort_NN ._.
Work_NN in_IN progress_NN has_VBZ been_VBN similarly_RB valued_VBN and_CC includes_VBZ an_DT allowance_NN for_IN the_DT costs_NNS to_TO complete_VB ._.
The_DT resulting_VBG fair_JJ value_NN adjustment_NN of_IN 4,686,000_CD has_VBZ been_VBN recognized_VBN ._.
The_DT acquisition_NN of_IN ACMI_NNP has_VBZ provided_VBN Gyrus_NNP with_IN the_DT opportunity_NN to_TO combine_VB ACMIs_NNP urology_NN ,_, gynaecology_NN and_CC endoscopic_JJ expertise_NN with_IN Gyruss_NNP tissue_NN management_NN technology_NN in_IN these_DT fields_NNS ._.
This_DT enables_VBZ the_DT enlarged_JJ Group_NNP to_TO meet_VB two_CD key_JJ requirements_NNS of_IN surgeons_NNS the_DT ability_NN to_TO visualise_VB the_DT operative_JJ site_NN and_CC the_DT ability_NN effectively_RB to_TO manipulate_VB tissue_NN with_IN minimum_JJ collateral_NN damage_NN ._.
Goodwill_NN of_IN 180_CD million_CD has_VBZ arisen_VBN as_IN a_DT result_NN of_IN the_DT synergistic_JJ and_CC integration_NN benefits_NNS of_IN combining_VBG the_DT two_CD organizations_NNS ._.
Since_IN the_DT date_NN of_IN acquisition_NN ,_, ACMI_NNP has_VBZ contributed_VBN the_DT following_VBG to_TO the_DT operating_NN profit_NN of_IN the_DT Group_NNP :_: 000_CD Revenue_NN 50,431_CD Cost_NN of_IN sales_NNS 23,805_CD Gross_NNP profit_NN 26,626_CD Selling_NNP and_CC distribution_NN expenses_NNS Selling_VBG and_CC distribution_NN 12,507_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 2,524_CD Research_NNP and_CC development_NN expenses_NNS Research_NNP and_CC development_NN 2,473_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 1,349_CD General_NNP and_CC administrative_JJ expenses_NNS 3,057_CD Operating_NN profit_NN 4,716_CD Had_VBD the_DT acquisition_NN taken_VBN place_NN on_IN 1_CD January_NNP 2005_CD ,_, ACMI_NNP would_MD have_VB contributed_VBN the_DT following_VBG to_TO the_DT operating_NN profit_NN of_IN the_DT Group_NNP :_: 000_CD Revenue_NN 111,920_CD Cost_NN of_IN sales_NNS 49,570_CD Gross_NNP profit_NN 62,350_CD Selling_NNP and_CC distribution_NN expenses_NNS Selling_VBG and_CC distribution_NN 27,805_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 5,706_CD Research_NNP and_CC development_NN expenses_NNS Research_NNP and_CC development_NN 6,277_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 3,050_CD General_NNP and_CC administrative_JJ expenses_NNS 8,511_CD Operating_NN profit_NN 11,001_CD Amortisation_NNP of_IN intangible_JJ assets_NNS as_IN if_IN acquisition_NN had_VBD occurred_VBN on_IN 1_CD January_NNP 2005_CD ._.
Restructuring_NN As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN American_JJ Cystoscope_NNP Makers_NNPS Inc_NNP ,_, a_DT number_NN of_IN restructuring_NN costs_NNS have_VBP been_VBN incurred_VBN across_IN the_DT Group_NNP ._.
The_DT total_JJ charge_NN for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2005_CD amounted_VBD to_TO 2,369,000_CD 2004_CD :_: nil_NN ._.
An_DT analysis_NN of_IN these_DT costs_NNS is_VBZ shown_VBN below_IN ._.
2005_CD 000_CD Severance_NN costs_NNS 1,320_CD Short_JJ term_NN sales_NNS commission_NN alignment_NN 352_CD Demonstration_NN equipment_NN write-off_NN 148_CD Alignment_NNP of_IN global_JJ enterprise_NN resource_NN planning_VBG systems_NNS 456_CD Other_JJ costs_NNS 93_CD 2,369_CD 4_CD ._.
Other_JJ operating_NN income_NN 2005 2004 000 000_CD Income_NN from_IN research_NN and_CC development_NN costs_NNS recharged_VBD to_TO third_JJ party_NN 1,501_CD 641_CD Gyrus_NNP Group_NNP PLC_NNP Annual_JJ Report_NNP and_CC Accounts_NNPS 2005_CD 58_CD
